Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
22 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Sanofi European Treasury Center from Brussel, company number BE0843874759, closed financial year 2025 with a result of € 2.4 million after tax. For that financial year Sanofi European Treasury Center recorded revenue of € 580,000 and equity of € 612,658. Compared with financial year 2024, the result moved from € 7.3 million to € 2.4 million. The company is profitable. The buffer shrank hard: equity is 100 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 612,658
▼ € 147.9 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.4 million
▼ 68% vs 2024
Profit after tax over the fiscal year.
€ 3.1 million
▼ 98% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 16.6 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
19.5
▲ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 5.1 million
▲ 10% vs 2024
€ 259,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 322,442
▲ 45% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 143 days on average.
€ 1.8 million
▲ 22% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 500,000 | € 550,000 | € 550,000 | € 580,000 | ▲ 5% |
| Profit after taxes | € 88,920,874 | € 50,806,043 | € 7,347,203 | € 2,373,889 | ▼ 68% |
| Equity | € 809,433,532 | € 220,512,658 | € 148,512,658 | € 612,658 | ▼ € 147.9 million |
| Total debts | € 19,985,747 | € 141,687,504 | € 9,002,523 | € 4,446,527 | ▼ 51% |
| Cash | € 640,563,966 | € 225,527,531 | € 153,640,111 | € 3,149,971 | ▼ 98% |
| Retained profit | € 175,203,695 | € 86,282,821 | € 14,282,821 | € 82,821 | ▼ 99% |
| Dividend | € 0 | € 139,726,918 | € 79,347,203 | € 16,573,889 | ▼ 79% |
| Balance sheet total | € 829,419,280 | € 362,200,163 | € 157,515,181 | € 5,059,185 | ▼ 97% |
| Employees (FTE) | 18.3 | 19 | 19 | 19.5 | ▲ 0.5 |
Key figures of Sanofi European Treasury Center, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Sanofi European Treasury Center the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Sanofi European Treasury Center?
What happened at Sanofi European Treasury Center in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Hao ZHENG stepped down as director. NBB
- Olivier KLARIC stepped down as director. NBB
- Alexandra ROGER stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.4 million (▼ 68% vs 2024). Source: NBB ↗
- Hao ZHENG became a director. NBB
- Alexandra ROGER became a director. NBB
- Olivier KLARIC became a director. NBB
- Capital increase of € 2.1 billion, published in the Gazette. Source: Staatsblad ↗
In short
From € 88.9 million profit in 2022 to € 2.4 million profit in 2025.
Paid € 33.7 million in corporate taxes since 2022.
Best year ever: 2022, with € 88.9 million profit.
Paid out € 235.6 million in dividends to the owners in total.
Management
Directors
According to the 2025 annual accounts
Olivier KLARIC
Director
since 2023 · until 2029
Alexandra ROGER
Director
since 2024 · until 2029
Hao ZHENG
Director
since 2025 · until 2030
Establishments
Establishment units
Physical locations of this company
Wetenschapsstraat 14
1040 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 22 companies are registered at this address.
All companies at this address →Belgian Millers
Union Royale des Torréfacteurs de café
Groepering van de Roomijsindustrie - Groupement de l'Industrie des Crèmes Glacées
FEDERATION DE L'INDUSTRIE ALIMENTAIRE - FEDERATIE VOEDINGSINDUSTRIE
€ 1.1 million revenue · 2025
KONINKLIJKE BELGISCHE VERENIGING VAN DE BISCUIT CHOCOLADE SUIKERGOED EN PRALINE-INDUSTRIE - ASSOCIATION ROYALE BELGE DES INDUSTRIES DU BISCUIT DU CHOCOLAT DE L
+17 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Capital increase
Source: Deed ↗- Sanofi Aventis Europe(inschrijver) 100%
Incorporation
Source: Deed ↗- Sanofi-Aventis Europe(oprichter) 99.8%
- Sanofi-Aventis Groupe(oprichter) 0.2%
Details
- Company number
- 0843.874.759
- VAT number
- BE 0843.874.759
- Registered office
- Wetenschapsstraat 14, 1040 Brussel
- Names & denominations
- Sanofi European Treasury Center · SETC
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 February 2012
- Peppol
- Active · Active since 2 Jun 2026
- Activities · NACE
Overige zakelijke dienstverlening, neg
Overige financiële dienstverlening, neg